Seaport Research lowered the firm’s price target on Ascend Wellness to $5 from $6 and keeps a Buy rating on the shares. After four quarters of beating revenue and AEBITDA estimates, the company reported Q2 results that were below the firm’s expectations, the analyst tells investors. Despite this, Seaport continues to believe the company’s strong execution, retail prowess, and marketing & acquisition upside make it the “most underappreciated” story in the cannabis sector.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AAWH: